Sarepta Therapeutics downgraded by Barclays with a new price target
$SRPT
Biotechnology: Pharmaceutical Preparations
Health Care
Barclays downgraded Sarepta Therapeutics from Equal Weight to Underweight and set a new price target of $10.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/29/2025 | $22.00 | Underweight → Equal Weight | Barclays |
| 7/29/2025 | $13.00 | Mkt Perform | Bernstein |
| 7/29/2025 | $37.00 | Perform → Outperform | Oppenheimer |
| 7/29/2025 | $24.00 | Underweight → Neutral | Analyst |
| 7/29/2025 | $5.00 | Sell | H.C. Wainwright |
| 7/28/2025 | $10.00 | Equal Weight → Underweight | Barclays |
| 7/25/2025 | Neutral → Underweight | Analyst | |
| 7/24/2025 | $7.00 | Sell | Citigroup |
4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)
4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)
4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)
Submission status for SAREPTA THERAPS INC's drug AMONDYS 45 (SUPPL-8) with active ingredient CASIMERSEN has changed to 'Approval' on 07/11/2024. Application Category: NDA, Application Number: 213026, Application Classification: Labeling
For Immediate Release: June 20, 2024 Today, the U.S. Food and Drug Administration expanded the approval of Elevidys (delandistrogene moxeparvovec-rokl), a gene therapy for the treatment of Duchenne muscular dystrophy (DMD) for ambulatory and non-ambulatory individuals 4 years of age and older with DMD with a confirmed mutation in the DMD gene. Elevidys was previously approved under accelerated approval for amb
Submission status for SAREPTA THERAPS INC's drug VYONDYS 53 (SUPPL-11) with active ingredient GOLODIRSEN has changed to 'Approval' on 06/04/2024. Application Category: NDA, Application Number: 211970, Application Classification: Labeling
Barclays upgraded Sarepta Therapeutics from Underweight to Equal Weight and set a new price target of $22.00
Bernstein initiated coverage of Sarepta Therapeutics with a rating of Mkt Perform and set a new price target of $13.00
Oppenheimer upgraded Sarepta Therapeutics from Perform to Outperform and set a new price target of $37.00
4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)
4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)
4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)
- Safety review leading to dose escalation and achievement of first predetermined enrollment target in Phase 1/2 study of SRP-1003 for DM1 triggers $100 million milestone payment - Sarepta sells at least $174 million of Arrowhead common stock for cash proceeds, Arrowhead will redeem $50 million of stock from Sarepta to prefund half of $100 million milestone payment due to Arrowhead Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that it has sold 9,265,312 shares of common stock of Arrowhead Pharmaceuticals, Inc. ("Arrowhead") in a privately negotiated block trade. The Company expects to receive at least $174 million i
ELEVIDYS shipments have resumed for ambulatory individuals living with Duchenne following notification from the U.S. Food and Drug Administration (FDA); continuing to work with FDA on safety labeling process and risk-mitigation approach for non-ambulatory individuals Net product revenues for the second quarter 2025 totaled $513.1 million, a 42% increase over the same quarter of the prior year Previously announced restructuring advancing as planned; on track to realize over $100 million in cost savings through the end of 2025 Multiple clinical data readouts and milestones expected in 2025 and into early 2026 to support siRNA franchise - FSHD, DM1, SCA2, and Huntington's Disease
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report second quarter 2025 financial results after the Nasdaq Global Market closes on Wednesday, August 6, 2025. As announced on July 16, 2025, the Company will not be hosting a conference call to discuss results at this time. About Sarepta Therapeutics Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold leadership positions in Duchenne muscular dystrophy (Duchenne) and are building a robust portfolio of programs across muscle, central nervous system, and cardiac diseases. For more information, ple
8-K - Sarepta Therapeutics, Inc. (0000873303) (Filer)
S-8 - Sarepta Therapeutics, Inc. (0000873303) (Filer)
10-Q - Sarepta Therapeutics, Inc. (0000873303) (Filer)
- Veteran biopharmaceutical executive from GSK and Eli Lilly brings more than 30 years of experience to Sarepta's Board Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the appointment of Deirdre P. Connelly to its Board of Directors. Ms. Connelly is a well-regarded executive with more than 30 years of experience in the pharmaceutical industry. Following Connelly's appointment, Sarepta's Board will comprise nine directors, eight of whom are independent. "Ms. Connelly is a seasoned board leader with extensive operating experience in biopharma and we're pleased to welcome her to the Sarepta Board of Directors as we work to
Rick Barry appointed Executive Chairman of the BoardRemi Barbier resigns as President and CEO and from the Board of DirectorsCassava initiates search for a new CEO AUSTIN, Texas, July 17, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA) today announced that the Board of Directors has appointed Richard (Rick) Barry as Executive Chairman of the Board and as the Company's principal executive officer, effective immediately. The Company is undertaking a search for a new permanent CEO. Mr. Barry succeeds Remi Barbier, the Company's Chairman, President and CEO, who resigned from the Company and the Board. Mr. Barbier will remain employed by the Company until September 13, 2024 in a
NEW YORK, May 29, 2024 /PRNewswire/ -- Sarepta Therapeutics Inc. (NASD: SRPT) will replace Shockwave Medical Inc. (NASD: SWAV) in the S&P MidCap 400 effective prior to the opening of trading on Monday, June 3. S&P 500 constituent Johnson & Johnson (NYSE:JNJ) is acquiring Shockwave Medical in a deal expected to be completed soon pending final closing conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector June 3, 2024 S&P MidCap 400 Addition Sarepta Therapeutics SRPT Health Care June 3, 2024 S&P MidCap 400 Deletion Shockwave Medical SWAV Health Care For
ELEVIDYS shipments have resumed for ambulatory individuals living with Duchenne following notification from the U.S. Food and Drug Administration (FDA); continuing to work with FDA on safety labeling process and risk-mitigation approach for non-ambulatory individuals Net product revenues for the second quarter 2025 totaled $513.1 million, a 42% increase over the same quarter of the prior year Previously announced restructuring advancing as planned; on track to realize over $100 million in cost savings through the end of 2025 Multiple clinical data readouts and milestones expected in 2025 and into early 2026 to support siRNA franchise - FSHD, DM1, SCA2, and Huntington's Disease
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report second quarter 2025 financial results after the Nasdaq Global Market closes on Wednesday, August 6, 2025. As announced on July 16, 2025, the Company will not be hosting a conference call to discuss results at this time. About Sarepta Therapeutics Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold leadership positions in Duchenne muscular dystrophy (Duchenne) and are building a robust portfolio of programs across muscle, central nervous system, and cardiac diseases. For more information, ple
– After strategic review, Sarepta focuses pipeline on high-impact programs, prioritizing potentially best-in-class siRNA platform assets – Strategic restructuring includes reduced operating expenses, delivering approximately $400 million in anticipated annual cost savings, and implementing a 36% workforce reduction of approximately 500 employees – Duchenne portfolio continues to deliver stable and robust revenues, with preliminary quarterly results showing total net product revenue of $513 million for the second quarter 2025 – U.S. FDA has requested and Sarepta has agreed to include a black box warning in the ELEVIDYS label, resolving any material issues with the ambulant population i
SC 13G/A - Sarepta Therapeutics, Inc. (0000873303) (Subject)
SC 13G - Sarepta Therapeutics, Inc. (0000873303) (Subject)
SC 13G/A - Sarepta Therapeutics, Inc. (0000873303) (Subject)